nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—Flank pain—Vismodegib—skin cancer	0.0433	0.0585	CcSEcCtD
Methysergide—Telangiectasia—Fluorouracil—skin cancer	0.0215	0.0291	CcSEcCtD
Methysergide—Leg edema—Temozolomide—skin cancer	0.0204	0.0276	CcSEcCtD
Methysergide—Blood urea increased—Vismodegib—skin cancer	0.0165	0.0222	CcSEcCtD
Methysergide—Pain in extremity—Vismodegib—skin cancer	0.0127	0.0171	CcSEcCtD
Methysergide—Hyperaesthesia—Imiquimod—skin cancer	0.0117	0.0158	CcSEcCtD
Methysergide—Weight decreased—Vismodegib—skin cancer	0.00989	0.0134	CcSEcCtD
Methysergide—HTR2A—hindlimb—skin cancer	0.00871	0.0559	CbGeAlD
Methysergide—HTR1B—blood vessel—skin cancer	0.00865	0.0555	CbGeAlD
Methysergide—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00862	0.0117	CcSEcCtD
Methysergide—HTR7—nerve—skin cancer	0.0085	0.0545	CbGeAlD
Methysergide—HTR1D—blood vessel—skin cancer	0.00838	0.0538	CbGeAlD
Methysergide—Hyperaesthesia—Bleomycin—skin cancer	0.00831	0.0112	CcSEcCtD
Methysergide—Pain in extremity—Vemurafenib—skin cancer	0.00782	0.0106	CcSEcCtD
Methysergide—Alopecia—Vismodegib—skin cancer	0.00773	0.0105	CcSEcCtD
Methysergide—HTR2A—appendage—skin cancer	0.00747	0.048	CbGeAlD
Methysergide—Back pain—Vismodegib—skin cancer	0.00737	0.00996	CcSEcCtD
Methysergide—Heartburn—Fluorouracil—skin cancer	0.00737	0.00996	CcSEcCtD
Methysergide—HTR7—endothelium—skin cancer	0.00724	0.0464	CbGeAlD
Methysergide—Hyperaesthesia—Temozolomide—skin cancer	0.00701	0.00948	CcSEcCtD
Methysergide—Eosinophilia—Vemurafenib—skin cancer	0.00669	0.00904	CcSEcCtD
Methysergide—HTR7—blood vessel—skin cancer	0.00667	0.0428	CbGeAlD
Methysergide—Pain in extremity—Imiquimod—skin cancer	0.00667	0.00901	CcSEcCtD
Methysergide—Myalgia—Vismodegib—skin cancer	0.00649	0.00877	CcSEcCtD
Methysergide—Arthralgia—Vismodegib—skin cancer	0.00649	0.00877	CcSEcCtD
Methysergide—HTR1F—head—skin cancer	0.00638	0.0409	CbGeAlD
Methysergide—Weight decreased—Vemurafenib—skin cancer	0.00611	0.00826	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00566	0.00766	CcSEcCtD
Methysergide—SIGMAR1—nipple—skin cancer	0.00565	0.0362	CbGeAlD
Methysergide—HTR1E—head—skin cancer	0.00553	0.0355	CbGeAlD
Methysergide—Dyspepsia—Vismodegib—skin cancer	0.00547	0.0074	CcSEcCtD
Methysergide—Dysuria—Imiquimod—skin cancer	0.00539	0.00728	CcSEcCtD
Methysergide—Gastrointestinal disorder—Vismodegib—skin cancer	0.00537	0.00726	CcSEcCtD
Methysergide—Fatigue—Vismodegib—skin cancer	0.00536	0.00725	CcSEcCtD
Methysergide—Oedema peripheral—Vemurafenib—skin cancer	0.00533	0.0072	CcSEcCtD
Methysergide—Heartburn—Docetaxel—skin cancer	0.00532	0.00719	CcSEcCtD
Methysergide—Pain—Vismodegib—skin cancer	0.00532	0.00719	CcSEcCtD
Methysergide—Constipation—Vismodegib—skin cancer	0.00532	0.00719	CcSEcCtD
Methysergide—HTR2A—nerve—skin cancer	0.0053	0.034	CbGeAlD
Methysergide—Gastrointestinal pain—Vismodegib—skin cancer	0.00508	0.00687	CcSEcCtD
Methysergide—Abdominal pain—Vismodegib—skin cancer	0.00492	0.00664	CcSEcCtD
Methysergide—Pleural effusion—Docetaxel—skin cancer	0.00478	0.00646	CcSEcCtD
Methysergide—Alopecia—Vemurafenib—skin cancer	0.00478	0.00646	CcSEcCtD
Methysergide—HTR7—neck—skin cancer	0.00477	0.0306	CbGeAlD
Methysergide—Thrombophlebitis—Temozolomide—skin cancer	0.00461	0.00624	CcSEcCtD
Methysergide—Back pain—Vemurafenib—skin cancer	0.00455	0.00615	CcSEcCtD
Methysergide—HTR2A—endothelium—skin cancer	0.00451	0.029	CbGeAlD
Methysergide—Asthenia—Vismodegib—skin cancer	0.00446	0.00603	CcSEcCtD
Methysergide—Euphoric mood—Fluorouracil—skin cancer	0.00436	0.00589	CcSEcCtD
Methysergide—HTR6—head—skin cancer	0.00434	0.0278	CbGeAlD
Methysergide—HTR1D—connective tissue—skin cancer	0.00429	0.0276	CbGeAlD
Methysergide—Flushing—Imiquimod—skin cancer	0.00428	0.00578	CcSEcCtD
Methysergide—Diarrhoea—Vismodegib—skin cancer	0.00425	0.00575	CcSEcCtD
Methysergide—Thrombophlebitis—Fluorouracil—skin cancer	0.00425	0.00575	CcSEcCtD
Methysergide—HTR2A—blood vessel—skin cancer	0.00416	0.0267	CbGeAlD
Methysergide—Alopecia—Imiquimod—skin cancer	0.00407	0.00551	CcSEcCtD
Methysergide—Arthralgia—Vemurafenib—skin cancer	0.00401	0.00542	CcSEcCtD
Methysergide—Myalgia—Vemurafenib—skin cancer	0.00401	0.00542	CcSEcCtD
Methysergide—Oliguria—Docetaxel—skin cancer	0.00397	0.00537	CcSEcCtD
Methysergide—Vomiting—Vismodegib—skin cancer	0.00395	0.00534	CcSEcCtD
Methysergide—Rash—Vismodegib—skin cancer	0.00392	0.0053	CcSEcCtD
Methysergide—Dermatitis—Vismodegib—skin cancer	0.00392	0.00529	CcSEcCtD
Methysergide—Back pain—Imiquimod—skin cancer	0.00388	0.00525	CcSEcCtD
Methysergide—Ataxia—Temozolomide—skin cancer	0.00376	0.00508	CcSEcCtD
Methysergide—Ill-defined disorder—Imiquimod—skin cancer	0.00372	0.00503	CcSEcCtD
Methysergide—Weight decreased—Bleomycin—skin cancer	0.0037	0.00501	CcSEcCtD
Methysergide—Nausea—Vismodegib—skin cancer	0.00369	0.00499	CcSEcCtD
Methysergide—Malaise—Imiquimod—skin cancer	0.00362	0.00489	CcSEcCtD
Methysergide—HTR2B—skin of body—skin cancer	0.00361	0.0232	CbGeAlD
Methysergide—Neutropenia—Dactinomycin—skin cancer	0.00357	0.00482	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.0035	0.00473	CcSEcCtD
Methysergide—Convulsion—Imiquimod—skin cancer	0.00348	0.0047	CcSEcCtD
Methysergide—Ataxia—Fluorouracil—skin cancer	0.00346	0.00468	CcSEcCtD
Methysergide—HTR7—connective tissue—skin cancer	0.00342	0.022	CbGeAlD
Methysergide—Arthralgia—Imiquimod—skin cancer	0.00342	0.00462	CcSEcCtD
Methysergide—Chest pain—Imiquimod—skin cancer	0.00342	0.00462	CcSEcCtD
Methysergide—Myalgia—Imiquimod—skin cancer	0.00342	0.00462	CcSEcCtD
Methysergide—Discomfort—Imiquimod—skin cancer	0.00338	0.00456	CcSEcCtD
Methysergide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00332	0.00448	CcSEcCtD
Methysergide—Fatigue—Vemurafenib—skin cancer	0.00331	0.00448	CcSEcCtD
Methysergide—SIGMAR1—mammalian vulva—skin cancer	0.0033	0.0212	CbGeAlD
Methysergide—Constipation—Vemurafenib—skin cancer	0.00328	0.00444	CcSEcCtD
Methysergide—Oedema—Imiquimod—skin cancer	0.00328	0.00443	CcSEcCtD
Methysergide—Lightheadedness—Docetaxel—skin cancer	0.00327	0.00443	CcSEcCtD
Methysergide—HTR7—epithelium—skin cancer	0.00325	0.0208	CbGeAlD
Methysergide—Neutropenia—Temozolomide—skin cancer	0.00323	0.00436	CcSEcCtD
Methysergide—Dysuria—Temozolomide—skin cancer	0.00323	0.00436	CcSEcCtD
Methysergide—Tachycardia—Imiquimod—skin cancer	0.0032	0.00432	CcSEcCtD
Methysergide—Eosinophilia—Fluorouracil—skin cancer	0.00315	0.00426	CcSEcCtD
Methysergide—Weight increased—Temozolomide—skin cancer	0.00314	0.00425	CcSEcCtD
Methysergide—HTR1B—female reproductive system—skin cancer	0.00313	0.0201	CbGeAlD
Methysergide—Weight decreased—Temozolomide—skin cancer	0.00312	0.00422	CcSEcCtD
Methysergide—Thrombophlebitis—Docetaxel—skin cancer	0.00307	0.00415	CcSEcCtD
Methysergide—Flushing—Bleomycin—skin cancer	0.00304	0.00411	CcSEcCtD
Methysergide—Body temperature increased—Vemurafenib—skin cancer	0.00304	0.0041	CcSEcCtD
Methysergide—HTR1D—female reproductive system—skin cancer	0.00303	0.0194	CbGeAlD
Methysergide—HTR2C—female reproductive system—skin cancer	0.003	0.0192	CbGeAlD
Methysergide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00298	0.00403	CcSEcCtD
Methysergide—HTR2A—neck—skin cancer	0.00298	0.0191	CbGeAlD
Methysergide—Insomnia—Imiquimod—skin cancer	0.00296	0.00401	CcSEcCtD
Methysergide—Paraesthesia—Imiquimod—skin cancer	0.00294	0.00398	CcSEcCtD
Methysergide—Dyspnoea—Imiquimod—skin cancer	0.00292	0.00395	CcSEcCtD
Methysergide—Somnolence—Imiquimod—skin cancer	0.00291	0.00394	CcSEcCtD
Methysergide—Alopecia—Bleomycin—skin cancer	0.00289	0.00391	CcSEcCtD
Methysergide—Dyspepsia—Imiquimod—skin cancer	0.00288	0.0039	CcSEcCtD
Methysergide—Flushing—Dactinomycin—skin cancer	0.00284	0.00383	CcSEcCtD
Methysergide—Gastrointestinal disorder—Imiquimod—skin cancer	0.00283	0.00382	CcSEcCtD
Methysergide—Fatigue—Imiquimod—skin cancer	0.00282	0.00382	CcSEcCtD
Methysergide—HTR2B—female reproductive system—skin cancer	0.00282	0.0181	CbGeAlD
Methysergide—Pain—Imiquimod—skin cancer	0.0028	0.00379	CcSEcCtD
Methysergide—Asthenia—Vemurafenib—skin cancer	0.00276	0.00373	CcSEcCtD
Methysergide—Oedema peripheral—Temozolomide—skin cancer	0.00272	0.00368	CcSEcCtD
Methysergide—Alopecia—Dactinomycin—skin cancer	0.0027	0.00365	CcSEcCtD
Methysergide—Feeling abnormal—Imiquimod—skin cancer	0.0027	0.00365	CcSEcCtD
Methysergide—Gastrointestinal pain—Imiquimod—skin cancer	0.00268	0.00362	CcSEcCtD
Methysergide—Pain in extremity—Docetaxel—skin cancer	0.00266	0.00359	CcSEcCtD
Methysergide—Ill-defined disorder—Bleomycin—skin cancer	0.00265	0.00358	CcSEcCtD
Methysergide—Diarrhoea—Vemurafenib—skin cancer	0.00263	0.00355	CcSEcCtD
Methysergide—HTR1B—head—skin cancer	0.00261	0.0168	CbGeAlD
Methysergide—Abdominal pain—Imiquimod—skin cancer	0.00259	0.0035	CcSEcCtD
Methysergide—Body temperature increased—Imiquimod—skin cancer	0.00259	0.0035	CcSEcCtD
Methysergide—Malaise—Bleomycin—skin cancer	0.00257	0.00348	CcSEcCtD
Methysergide—Flushing—Temozolomide—skin cancer	0.00256	0.00347	CcSEcCtD
Methysergide—Dizziness—Vemurafenib—skin cancer	0.00254	0.00343	CcSEcCtD
Methysergide—HTR1D—head—skin cancer	0.00253	0.0162	CbGeAlD
Methysergide—HTR2C—head—skin cancer	0.00251	0.0161	CbGeAlD
Methysergide—Ataxia—Docetaxel—skin cancer	0.0025	0.00338	CcSEcCtD
Methysergide—Ill-defined disorder—Dactinomycin—skin cancer	0.00247	0.00334	CcSEcCtD
Methysergide—Vomiting—Vemurafenib—skin cancer	0.00244	0.0033	CcSEcCtD
Methysergide—Alopecia—Temozolomide—skin cancer	0.00244	0.0033	CcSEcCtD
Methysergide—Chest pain—Bleomycin—skin cancer	0.00243	0.00328	CcSEcCtD
Methysergide—Myalgia—Bleomycin—skin cancer	0.00243	0.00328	CcSEcCtD
Methysergide—Orthostatic hypotension—Docetaxel—skin cancer	0.00243	0.00328	CcSEcCtD
Methysergide—Rash—Vemurafenib—skin cancer	0.00242	0.00327	CcSEcCtD
Methysergide—Dermatitis—Vemurafenib—skin cancer	0.00242	0.00327	CcSEcCtD
Methysergide—HTR7—female reproductive system—skin cancer	0.00241	0.0155	CbGeAlD
Methysergide—Discomfort—Bleomycin—skin cancer	0.0024	0.00324	CcSEcCtD
Methysergide—Malaise—Dactinomycin—skin cancer	0.0024	0.00324	CcSEcCtD
Methysergide—HTR2B—head—skin cancer	0.00235	0.0151	CbGeAlD
Methysergide—Asthenia—Imiquimod—skin cancer	0.00235	0.00318	CcSEcCtD
Methysergide—Oedema—Bleomycin—skin cancer	0.00233	0.00315	CcSEcCtD
Methysergide—Back pain—Temozolomide—skin cancer	0.00233	0.00315	CcSEcCtD
Methysergide—Nausea—Vemurafenib—skin cancer	0.00228	0.00308	CcSEcCtD
Methysergide—Thrombocytopenia—Bleomycin—skin cancer	0.00228	0.00308	CcSEcCtD
Methysergide—Myalgia—Dactinomycin—skin cancer	0.00226	0.00306	CcSEcCtD
Methysergide—Alopecia—Fluorouracil—skin cancer	0.00225	0.00304	CcSEcCtD
Methysergide—Diarrhoea—Imiquimod—skin cancer	0.00224	0.00303	CcSEcCtD
Methysergide—Discomfort—Dactinomycin—skin cancer	0.00224	0.00302	CcSEcCtD
Methysergide—Ill-defined disorder—Temozolomide—skin cancer	0.00223	0.00302	CcSEcCtD
Methysergide—Oedema—Dactinomycin—skin cancer	0.00217	0.00293	CcSEcCtD
Methysergide—Malaise—Temozolomide—skin cancer	0.00217	0.00293	CcSEcCtD
Methysergide—Dizziness—Imiquimod—skin cancer	0.00217	0.00293	CcSEcCtD
Methysergide—Neutropenia—Docetaxel—skin cancer	0.00215	0.0029	CcSEcCtD
Methysergide—HTR2A—connective tissue—skin cancer	0.00213	0.0137	CbGeAlD
Methysergide—Thrombocytopenia—Dactinomycin—skin cancer	0.00213	0.00287	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00212	0.00287	CcSEcCtD
Methysergide—HTR1A—head—skin cancer	0.00211	0.0135	CbGeAlD
Methysergide—Paraesthesia—Bleomycin—skin cancer	0.00209	0.00282	CcSEcCtD
Methysergide—Weight increased—Docetaxel—skin cancer	0.00209	0.00282	CcSEcCtD
Methysergide—Convulsion—Temozolomide—skin cancer	0.00208	0.00282	CcSEcCtD
Methysergide—Vomiting—Imiquimod—skin cancer	0.00208	0.00282	CcSEcCtD
Methysergide—Weight decreased—Docetaxel—skin cancer	0.00208	0.00281	CcSEcCtD
Methysergide—Dyspnoea—Bleomycin—skin cancer	0.00207	0.0028	CcSEcCtD
Methysergide—Rash—Imiquimod—skin cancer	0.00207	0.00279	CcSEcCtD
Methysergide—Dermatitis—Imiquimod—skin cancer	0.00206	0.00279	CcSEcCtD
Methysergide—Arthralgia—Temozolomide—skin cancer	0.00205	0.00277	CcSEcCtD
Methysergide—Myalgia—Temozolomide—skin cancer	0.00205	0.00277	CcSEcCtD
Methysergide—HTR2A—epithelium—skin cancer	0.00203	0.013	CbGeAlD
Methysergide—Discomfort—Temozolomide—skin cancer	0.00202	0.00274	CcSEcCtD
Methysergide—HTR7—head—skin cancer	0.00202	0.0129	CbGeAlD
Methysergide—Pain—Bleomycin—skin cancer	0.00199	0.00269	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00198	0.00267	CcSEcCtD
Methysergide—Oedema—Temozolomide—skin cancer	0.00196	0.00265	CcSEcCtD
Methysergide—Nausea—Imiquimod—skin cancer	0.00195	0.00263	CcSEcCtD
Methysergide—Thrombocytopenia—Temozolomide—skin cancer	0.00192	0.0026	CcSEcCtD
Methysergide—Convulsion—Fluorouracil—skin cancer	0.00192	0.0026	CcSEcCtD
Methysergide—Feeling abnormal—Bleomycin—skin cancer	0.00192	0.00259	CcSEcCtD
Methysergide—Chest pain—Fluorouracil—skin cancer	0.00189	0.00255	CcSEcCtD
Methysergide—Myalgia—Fluorouracil—skin cancer	0.00189	0.00255	CcSEcCtD
Methysergide—Fatigue—Dactinomycin—skin cancer	0.00187	0.00253	CcSEcCtD
Methysergide—Discomfort—Fluorouracil—skin cancer	0.00186	0.00252	CcSEcCtD
Methysergide—Pain—Dactinomycin—skin cancer	0.00186	0.00251	CcSEcCtD
Methysergide—Body temperature increased—Bleomycin—skin cancer	0.00184	0.00249	CcSEcCtD
Methysergide—Oedema peripheral—Docetaxel—skin cancer	0.00181	0.00245	CcSEcCtD
Methysergide—Oedema—Fluorouracil—skin cancer	0.00181	0.00245	CcSEcCtD
Methysergide—Feeling abnormal—Dactinomycin—skin cancer	0.00179	0.00242	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00179	0.00242	CcSEcCtD
Methysergide—Insomnia—Temozolomide—skin cancer	0.00178	0.0024	CcSEcCtD
Methysergide—Gastrointestinal pain—Dactinomycin—skin cancer	0.00177	0.0024	CcSEcCtD
Methysergide—Thrombocytopenia—Fluorouracil—skin cancer	0.00177	0.00239	CcSEcCtD
Methysergide—Tachycardia—Fluorouracil—skin cancer	0.00177	0.00239	CcSEcCtD
Methysergide—Paraesthesia—Temozolomide—skin cancer	0.00176	0.00238	CcSEcCtD
Methysergide—Dyspnoea—Temozolomide—skin cancer	0.00175	0.00237	CcSEcCtD
Methysergide—Somnolence—Temozolomide—skin cancer	0.00175	0.00236	CcSEcCtD
Methysergide—Dyspepsia—Temozolomide—skin cancer	0.00173	0.00234	CcSEcCtD
Methysergide—Abdominal pain—Dactinomycin—skin cancer	0.00172	0.00232	CcSEcCtD
Methysergide—Body temperature increased—Dactinomycin—skin cancer	0.00172	0.00232	CcSEcCtD
Methysergide—Flushing—Docetaxel—skin cancer	0.00171	0.00231	CcSEcCtD
Methysergide—Gastrointestinal disorder—Temozolomide—skin cancer	0.00169	0.00229	CcSEcCtD
Methysergide—Fatigue—Temozolomide—skin cancer	0.00169	0.00229	CcSEcCtD
Methysergide—Constipation—Temozolomide—skin cancer	0.00168	0.00227	CcSEcCtD
Methysergide—Pain—Temozolomide—skin cancer	0.00168	0.00227	CcSEcCtD
Methysergide—Asthenia—Bleomycin—skin cancer	0.00167	0.00226	CcSEcCtD
Methysergide—SIGMAR1—lymph node—skin cancer	0.00165	0.0106	CbGeAlD
Methysergide—HTR2B—lymph node—skin cancer	0.00165	0.0106	CbGeAlD
Methysergide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00165	0.00223	CcSEcCtD
Methysergide—Insomnia—Fluorouracil—skin cancer	0.00164	0.00221	CcSEcCtD
Methysergide—Paraesthesia—Fluorouracil—skin cancer	0.00162	0.0022	CcSEcCtD
Methysergide—Alopecia—Docetaxel—skin cancer	0.00162	0.0022	CcSEcCtD
Methysergide—Feeling abnormal—Temozolomide—skin cancer	0.00162	0.00219	CcSEcCtD
Methysergide—Dyspnoea—Fluorouracil—skin cancer	0.00161	0.00218	CcSEcCtD
Methysergide—Somnolence—Fluorouracil—skin cancer	0.00161	0.00217	CcSEcCtD
Methysergide—Gastrointestinal pain—Temozolomide—skin cancer	0.00161	0.00217	CcSEcCtD
Methysergide—Dyspepsia—Fluorouracil—skin cancer	0.00159	0.00215	CcSEcCtD
Methysergide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00156	0.00211	CcSEcCtD
Methysergide—Asthenia—Dactinomycin—skin cancer	0.00156	0.00211	CcSEcCtD
Methysergide—Abdominal pain—Temozolomide—skin cancer	0.00155	0.0021	CcSEcCtD
Methysergide—Body temperature increased—Temozolomide—skin cancer	0.00155	0.0021	CcSEcCtD
Methysergide—Back pain—Docetaxel—skin cancer	0.00155	0.00209	CcSEcCtD
Methysergide—Pain—Fluorouracil—skin cancer	0.00155	0.00209	CcSEcCtD
Methysergide—HTR2A—female reproductive system—skin cancer	0.0015	0.00966	CbGeAlD
Methysergide—Feeling abnormal—Fluorouracil—skin cancer	0.00149	0.00201	CcSEcCtD
Methysergide—Diarrhoea—Dactinomycin—skin cancer	0.00149	0.00201	CcSEcCtD
Methysergide—Vomiting—Bleomycin—skin cancer	0.00148	0.002	CcSEcCtD
Methysergide—Rash—Bleomycin—skin cancer	0.00147	0.00198	CcSEcCtD
Methysergide—Dermatitis—Bleomycin—skin cancer	0.00147	0.00198	CcSEcCtD
Methysergide—Body temperature increased—Fluorouracil—skin cancer	0.00143	0.00193	CcSEcCtD
Methysergide—Asthenia—Temozolomide—skin cancer	0.00141	0.0019	CcSEcCtD
Methysergide—Convulsion—Docetaxel—skin cancer	0.00139	0.00187	CcSEcCtD
Methysergide—Nausea—Bleomycin—skin cancer	0.00138	0.00187	CcSEcCtD
Methysergide—Vomiting—Dactinomycin—skin cancer	0.00138	0.00187	CcSEcCtD
Methysergide—Rash—Dactinomycin—skin cancer	0.00137	0.00185	CcSEcCtD
Methysergide—Arthralgia—Docetaxel—skin cancer	0.00136	0.00184	CcSEcCtD
Methysergide—Chest pain—Docetaxel—skin cancer	0.00136	0.00184	CcSEcCtD
Methysergide—Myalgia—Docetaxel—skin cancer	0.00136	0.00184	CcSEcCtD
Methysergide—Diarrhoea—Temozolomide—skin cancer	0.00134	0.00182	CcSEcCtD
Methysergide—Oedema—Docetaxel—skin cancer	0.00131	0.00176	CcSEcCtD
Methysergide—Dizziness—Temozolomide—skin cancer	0.0013	0.00175	CcSEcCtD
Methysergide—Nausea—Dactinomycin—skin cancer	0.00129	0.00174	CcSEcCtD
Methysergide—Thrombocytopenia—Docetaxel—skin cancer	0.00128	0.00173	CcSEcCtD
Methysergide—Tachycardia—Docetaxel—skin cancer	0.00127	0.00172	CcSEcCtD
Methysergide—HTR2A—head—skin cancer	0.00126	0.00807	CbGeAlD
Methysergide—Vomiting—Temozolomide—skin cancer	0.00125	0.00169	CcSEcCtD
Methysergide—Rash—Temozolomide—skin cancer	0.00124	0.00167	CcSEcCtD
Methysergide—Diarrhoea—Fluorouracil—skin cancer	0.00124	0.00167	CcSEcCtD
Methysergide—Dermatitis—Temozolomide—skin cancer	0.00124	0.00167	CcSEcCtD
Methysergide—Dizziness—Fluorouracil—skin cancer	0.0012	0.00162	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00119	0.00161	CcSEcCtD
Methysergide—Insomnia—Docetaxel—skin cancer	0.00118	0.0016	CcSEcCtD
Methysergide—Paraesthesia—Docetaxel—skin cancer	0.00117	0.00158	CcSEcCtD
Methysergide—Nausea—Temozolomide—skin cancer	0.00117	0.00158	CcSEcCtD
Methysergide—Dyspnoea—Docetaxel—skin cancer	0.00116	0.00157	CcSEcCtD
Methysergide—Somnolence—Docetaxel—skin cancer	0.00116	0.00157	CcSEcCtD
Methysergide—Vomiting—Fluorouracil—skin cancer	0.00115	0.00155	CcSEcCtD
Methysergide—Dyspepsia—Docetaxel—skin cancer	0.00115	0.00155	CcSEcCtD
Methysergide—Rash—Fluorouracil—skin cancer	0.00114	0.00154	CcSEcCtD
Methysergide—Dermatitis—Fluorouracil—skin cancer	0.00114	0.00154	CcSEcCtD
Methysergide—Gastrointestinal disorder—Docetaxel—skin cancer	0.00113	0.00152	CcSEcCtD
Methysergide—Fatigue—Docetaxel—skin cancer	0.00113	0.00152	CcSEcCtD
Methysergide—Pain—Docetaxel—skin cancer	0.00112	0.00151	CcSEcCtD
Methysergide—Constipation—Docetaxel—skin cancer	0.00112	0.00151	CcSEcCtD
Methysergide—Feeling abnormal—Docetaxel—skin cancer	0.00108	0.00145	CcSEcCtD
Methysergide—Nausea—Fluorouracil—skin cancer	0.00107	0.00145	CcSEcCtD
Methysergide—Gastrointestinal pain—Docetaxel—skin cancer	0.00107	0.00144	CcSEcCtD
Methysergide—Abdominal pain—Docetaxel—skin cancer	0.00103	0.0014	CcSEcCtD
Methysergide—Body temperature increased—Docetaxel—skin cancer	0.00103	0.0014	CcSEcCtD
Methysergide—Asthenia—Docetaxel—skin cancer	0.000937	0.00127	CcSEcCtD
Methysergide—Diarrhoea—Docetaxel—skin cancer	0.000893	0.00121	CcSEcCtD
Methysergide—Dizziness—Docetaxel—skin cancer	0.000863	0.00117	CcSEcCtD
Methysergide—Vomiting—Docetaxel—skin cancer	0.00083	0.00112	CcSEcCtD
Methysergide—Rash—Docetaxel—skin cancer	0.000823	0.00111	CcSEcCtD
Methysergide—Dermatitis—Docetaxel—skin cancer	0.000822	0.00111	CcSEcCtD
Methysergide—Nausea—Docetaxel—skin cancer	0.000775	0.00105	CcSEcCtD
Methysergide—HTR1D—Signaling by GPCR—PTCH1—skin cancer	0.000161	0.00154	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—SMO—skin cancer	0.000161	0.00154	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—PTGER4—skin cancer	0.000159	0.00152	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—PTGER4—skin cancer	0.000158	0.00151	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—PTGER4—skin cancer	0.000158	0.00151	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—PTCH1—skin cancer	0.000158	0.00151	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—SMO—skin cancer	0.000158	0.00151	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SHH—skin cancer	0.000157	0.0015	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—PTGER4—skin cancer	0.000157	0.0015	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—SHH—skin cancer	0.000156	0.0015	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—RASA1—skin cancer	0.000156	0.00149	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MC1R—skin cancer	0.000154	0.00147	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—PTGER4—skin cancer	0.000153	0.00147	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—GLI2—skin cancer	0.000149	0.00142	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SMO—skin cancer	0.000149	0.00142	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—PTCH1—skin cancer	0.000149	0.00142	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—GLI2—skin cancer	0.000149	0.00142	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—SMO—skin cancer	0.000148	0.00142	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—PTCH1—skin cancer	0.000148	0.00142	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SHH—skin cancer	0.000148	0.00142	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—GLI2—skin cancer	0.000148	0.00141	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—RASA1—skin cancer	0.000147	0.00141	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000146	0.0014	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTCH2—skin cancer	0.000145	0.00139	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—PTGER4—skin cancer	0.000145	0.00139	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—GLI2—skin cancer	0.000145	0.00138	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTCH2—skin cancer	0.000145	0.00138	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—PTGER4—skin cancer	0.000144	0.00138	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MC1R—skin cancer	0.000142	0.00136	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MC1R—skin cancer	0.000142	0.00136	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MC1R—skin cancer	0.000141	0.00135	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PTCH1—skin cancer	0.00014	0.00134	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SMO—skin cancer	0.00014	0.00134	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—GLI1—skin cancer	0.00014	0.00134	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—GLI1—skin cancer	0.00014	0.00134	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—GLI1—skin cancer	0.000139	0.00133	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MC1R—skin cancer	0.000138	0.00132	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PTGER4—skin cancer	0.000137	0.00131	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—GLI1—skin cancer	0.000136	0.0013	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—GLI2—skin cancer	0.000136	0.0013	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SUFU—skin cancer	0.000133	0.00127	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SUFU—skin cancer	0.000132	0.00127	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SUFU—skin cancer	0.000132	0.00126	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MC1R—skin cancer	0.00013	0.00124	CbGpPWpGaD
Methysergide—HTR7—Circadian rythm related genes—TP53—skin cancer	0.000129	0.00124	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SUFU—skin cancer	0.000129	0.00123	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PTGER4—skin cancer	0.000129	0.00123	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PTGER4—skin cancer	0.000128	0.00123	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—FOXO4—skin cancer	0.000128	0.00123	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—GLI1—skin cancer	0.000128	0.00122	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—SHH—skin cancer	0.000127	0.00121	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—SHH—skin cancer	0.000126	0.00121	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000126	0.00121	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTCH2—skin cancer	0.000126	0.0012	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SUFU—skin cancer	0.000121	0.00116	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—FOXO4—skin cancer	0.000121	0.00116	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PTCH1—skin cancer	0.00012	0.00115	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—SMO—skin cancer	0.00012	0.00115	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PTCH1—skin cancer	0.000119	0.00114	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—SMO—skin cancer	0.000119	0.00114	CbGpPWpGaD
Methysergide—HTR7—Circadian rythm related genes—IL6—skin cancer	0.000118	0.00113	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000118	0.00113	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PTGER4—skin cancer	0.000117	0.00112	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PTGER4—skin cancer	0.000116	0.00111	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PTGER4—skin cancer	0.000111	0.00107	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GLI2—skin cancer	0.00011	0.00105	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GLI2—skin cancer	0.00011	0.00105	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—SHH—skin cancer	0.000109	0.00105	CbGpPWpGaD
Methysergide—HTR1A—SIDS Susceptibility Pathways—IL6—skin cancer	0.000107	0.00103	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000107	0.00103	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MC1R—skin cancer	0.000105	0.00101	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MC1R—skin cancer	0.000105	0.001	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—SMO—skin cancer	0.000104	0.000994	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PTCH1—skin cancer	0.000104	0.000994	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—GLI1—skin cancer	0.000104	0.000992	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—GLI1—skin cancer	0.000103	0.000986	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000103	0.000982	CbGpPWpGaD
Methysergide—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000102	0.000981	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000102	0.000973	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SHH—skin cancer	0.000101	0.000968	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PTGER4—skin cancer	0.000101	0.000968	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SHH—skin cancer	0.000101	0.000967	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RASA1—skin cancer	0.0001	0.000962	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RASA1—skin cancer	0.0001	0.000961	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SHH—skin cancer	0.0001	0.000961	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RASA1—skin cancer	9.97e-05	0.000955	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SHH—skin cancer	9.83e-05	0.000941	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SUFU—skin cancer	9.81e-05	0.00094	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RASA1—skin cancer	9.76e-05	0.000935	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SUFU—skin cancer	9.76e-05	0.000935	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTCH1—skin cancer	9.59e-05	0.000918	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SMO—skin cancer	9.59e-05	0.000918	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTCH1—skin cancer	9.58e-05	0.000917	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SMO—skin cancer	9.58e-05	0.000917	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GLI2—skin cancer	9.51e-05	0.000911	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTCH1—skin cancer	9.51e-05	0.000911	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SMO—skin cancer	9.51e-05	0.000911	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTGER4—skin cancer	9.33e-05	0.000894	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTGER4—skin cancer	9.32e-05	0.000893	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SMO—skin cancer	9.31e-05	0.000892	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTCH1—skin cancer	9.31e-05	0.000892	CbGpPWpGaD
Methysergide—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	9.28e-05	0.000889	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTGER4—skin cancer	9.26e-05	0.000887	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SHH—skin cancer	9.23e-05	0.000884	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RASA1—skin cancer	9.17e-05	0.000878	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MC1R—skin cancer	9.07e-05	0.000869	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTGER4—skin cancer	9.07e-05	0.000869	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GLI1—skin cancer	8.94e-05	0.000857	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	8.82e-05	0.000845	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTCH1—skin cancer	8.75e-05	0.000838	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SMO—skin cancer	8.75e-05	0.000838	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	8.64e-05	0.000827	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TERT—skin cancer	8.54e-05	0.000818	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTGER4—skin cancer	8.52e-05	0.000816	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SUFU—skin cancer	8.48e-05	0.000812	CbGpPWpGaD
Methysergide—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.27e-05	0.000792	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—FOXO4—skin cancer	8.24e-05	0.00079	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—FOXO4—skin cancer	8.23e-05	0.000789	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—FOXO4—skin cancer	8.18e-05	0.000784	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TERT—skin cancer	8.06e-05	0.000772	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—FOXO4—skin cancer	8.01e-05	0.000767	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—FOXO4—skin cancer	7.52e-05	0.000721	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.5e-05	0.000718	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SHH—skin cancer	7.48e-05	0.000717	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SHH—skin cancer	7.45e-05	0.000713	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RASA1—skin cancer	7.44e-05	0.000712	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RASA1—skin cancer	7.4e-05	0.000709	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—NRAS—skin cancer	7.2e-05	0.000689	CbGpPWpGaD
Methysergide—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	7.18e-05	0.000687	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SMO—skin cancer	7.1e-05	0.00068	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTCH1—skin cancer	7.1e-05	0.00068	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTCH1—skin cancer	7.06e-05	0.000676	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SMO—skin cancer	7.06e-05	0.000676	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTGER4—skin cancer	6.91e-05	0.000662	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTGER4—skin cancer	6.87e-05	0.000658	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—NRAS—skin cancer	6.79e-05	0.00065	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—BRAF—skin cancer	6.77e-05	0.000648	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SHH—skin cancer	6.47e-05	0.000619	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RASA1—skin cancer	6.43e-05	0.000615	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—BRAF—skin cancer	6.38e-05	0.000611	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—KRAS—skin cancer	6.2e-05	0.000593	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTCH1—skin cancer	6.13e-05	0.000587	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SMO—skin cancer	6.13e-05	0.000587	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—FOXO4—skin cancer	6.1e-05	0.000584	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—FOXO4—skin cancer	6.07e-05	0.000581	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTGER4—skin cancer	5.97e-05	0.000572	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—KRAS—skin cancer	5.84e-05	0.00056	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TERT—skin cancer	5.51e-05	0.000527	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TERT—skin cancer	5.5e-05	0.000527	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TERT—skin cancer	5.46e-05	0.000523	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TERT—skin cancer	5.35e-05	0.000512	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—FOXO4—skin cancer	5.27e-05	0.000505	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—HRAS—skin cancer	5.27e-05	0.000504	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—IL6—skin cancer	5.04e-05	0.000483	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TERT—skin cancer	5.03e-05	0.000481	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—HRAS—skin cancer	4.97e-05	0.000476	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—IL6—skin cancer	4.75e-05	0.000455	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—NRAS—skin cancer	4.64e-05	0.000444	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—NRAS—skin cancer	4.63e-05	0.000444	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—NRAS—skin cancer	4.6e-05	0.000441	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—NRAS—skin cancer	4.51e-05	0.000432	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—BRAF—skin cancer	4.36e-05	0.000418	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—BRAF—skin cancer	4.36e-05	0.000417	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—BRAF—skin cancer	4.33e-05	0.000414	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—NRAS—skin cancer	4.25e-05	0.000407	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—BRAF—skin cancer	4.24e-05	0.000406	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—NRAS—skin cancer	4.23e-05	0.000406	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TERT—skin cancer	4.08e-05	0.00039	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TERT—skin cancer	4.05e-05	0.000388	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NRAS—skin cancer	4.01e-05	0.000384	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—KRAS—skin cancer	3.99e-05	0.000382	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—KRAS—skin cancer	3.99e-05	0.000382	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—BRAF—skin cancer	3.98e-05	0.000381	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—KRAS—skin cancer	3.96e-05	0.000379	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—KRAS—skin cancer	3.88e-05	0.000372	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—KRAS—skin cancer	3.66e-05	0.000351	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—KRAS—skin cancer	3.64e-05	0.000349	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TERT—skin cancer	3.52e-05	0.000337	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—KRAS—skin cancer	3.45e-05	0.000331	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—NRAS—skin cancer	3.43e-05	0.000329	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—NRAS—skin cancer	3.42e-05	0.000327	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—HRAS—skin cancer	3.39e-05	0.000325	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—HRAS—skin cancer	3.39e-05	0.000325	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—HRAS—skin cancer	3.37e-05	0.000323	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—HRAS—skin cancer	3.3e-05	0.000316	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TP53—skin cancer	3.25e-05	0.000312	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL6—skin cancer	3.25e-05	0.000311	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL6—skin cancer	3.24e-05	0.000311	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—skin cancer	3.23e-05	0.000309	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—skin cancer	3.22e-05	0.000309	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—skin cancer	3.21e-05	0.000308	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—skin cancer	3.16e-05	0.000302	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—skin cancer	3.11e-05	0.000298	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—skin cancer	3.1e-05	0.000297	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—skin cancer	3.07e-05	0.000294	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—skin cancer	2.98e-05	0.000285	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—skin cancer	2.97e-05	0.000284	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—skin cancer	2.96e-05	0.000284	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—skin cancer	2.96e-05	0.000283	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—skin cancer	2.94e-05	0.000282	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—skin cancer	2.93e-05	0.000281	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—skin cancer	2.81e-05	0.000269	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—skin cancer	2.79e-05	0.000267	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—skin cancer	2.74e-05	0.000262	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—skin cancer	2.74e-05	0.000262	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—skin cancer	2.72e-05	0.00026	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—skin cancer	2.66e-05	0.000255	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—skin cancer	2.55e-05	0.000245	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—skin cancer	2.51e-05	0.000241	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—skin cancer	2.5e-05	0.00024	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—skin cancer	2.5e-05	0.000239	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—skin cancer	2.4e-05	0.00023	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—skin cancer	2.39e-05	0.000229	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—skin cancer	2.36e-05	0.000226	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—skin cancer	2.36e-05	0.000226	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—skin cancer	2.34e-05	0.000224	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—skin cancer	2.29e-05	0.000219	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—skin cancer	2.17e-05	0.000208	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—skin cancer	2.15e-05	0.000206	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—skin cancer	2.1e-05	0.000201	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—skin cancer	2.09e-05	0.000201	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—skin cancer	2.08e-05	0.000199	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—skin cancer	2.08e-05	0.000199	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—skin cancer	2.04e-05	0.000195	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—skin cancer	2.03e-05	0.000194	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—skin cancer	2.02e-05	0.000193	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—skin cancer	2e-05	0.000192	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—skin cancer	2e-05	0.000192	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—skin cancer	1.99e-05	0.000191	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—skin cancer	1.95e-05	0.000187	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—skin cancer	1.92e-05	0.000184	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—skin cancer	1.92e-05	0.000184	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—skin cancer	1.91e-05	0.000183	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—skin cancer	1.9e-05	0.000182	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—skin cancer	1.86e-05	0.000179	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—skin cancer	1.83e-05	0.000175	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—skin cancer	1.75e-05	0.000168	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—skin cancer	1.75e-05	0.000168	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—skin cancer	1.75e-05	0.000167	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—skin cancer	1.74e-05	0.000166	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—skin cancer	1.55e-05	0.000149	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—skin cancer	1.54e-05	0.000148	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—skin cancer	1.51e-05	0.000144	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—skin cancer	1.48e-05	0.000142	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—skin cancer	1.48e-05	0.000141	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—skin cancer	1.42e-05	0.000136	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—skin cancer	1.41e-05	0.000135	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—skin cancer	1.34e-05	0.000128	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—skin cancer	1.28e-05	0.000123	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—skin cancer	1.23e-05	0.000118	CbGpPWpGaD
